Yerem Yeghiazarians is a Cardiology physician affiliated with Rapt Therapeutics. OpenAlex indexes 159 publications with 8,353 citations (h-index 45); ClinicalTrials.gov lists 1 registered study matched to this name. By OpenAlex citation count, this profile ranks in the top 10% of Interventional Cardiology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
535 Mission Bay Blvd S
San Francisco, CA 941432156
Telephone
415-353-2873Provider last certified this registry record 5 Oct 2021.
Clinical trials
- The Role of Nitric Oxide Synthase in Circulating Progenitor Cell Function
Sponsor: University of California, San Francisco
- Effect of Cocoa Flavanols on Vascular Function
Sponsor: University of California, San Francisco
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Boston Scientific CorporationProgram year202517 payments
- Shockwave Medical, IncProgram year20251 payment
- Teleflex LLCProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cardiovascular
80.7%Statin24.6%Atorvastatin Calcium69%Rosuvastatin Calcium31%Part D<11 patientsCholesterol absorption inhibitor15.2%Ezetimibe100%Part D≥20 patients+ 5 more classes in this area
Blood & clotting
19.3%P2Y12 inhibitor16%Clopidogrel100%Part D≥20 patientsFactor Xa inhibitor3.3%Eliquis100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- International Consensus Statement on Obstructive Sleep Apnea
International Forum of Allergy & Rhinology
2022 - Obstructive Sleep Apnea in Cardiovascular Disease: A Review of the Literature and Proposed Multidisciplinary Clinical Management Strategy
Journal of the American Heart Association
2018
Similar KOLs
Other experts from the same institution or the same specialty.
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”